Bagheri Reza, Ranjbar Hassan
Radiation Applications Research School, Nuclear Science and Technology Research Institute, Tehran, Iran.
Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, Tehran, Iran.
Asia Ocean J Nucl Med Biol. 2025;13(1):94-101. doi: 10.22038/aojnmb.2024.79679.1560.
Liver malignancies are among the most prevalent causes of cancer-related deaths worldwide. Intra-arterial administration of particulates labeled with beta-emitting radionuclides is one of the non-surgical promising modalities for the treatment of liver cancer.
In this work, the radiation absorbed dose of Ho-hydroxyapatite (Ho-HA) radiopharmaceutical was estimated for adult men based on biodistribution data in normal Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied.
The results show that more than 84% of the absorbed dose is localized in liver tissue (7.35 mGy MBq). Also, radiation absorbed doses of Ho-HA for red bone marrow, osteogenic cells, and spleen tissues were estimated to be about 0.18, 0.38, and 0.24 mGy MBq, respectively. The maximum administrated activity was obtained at 87.5 MBq kg of body weight with an effective dose of 0.39 mSv MBq. The maximum tolerable dose (MTD) for liver tissue was 6.13 GBq (165.56 mCi).
This study indicated that Ho-HA can provide an impressive dose for liver cancer malignancies with an insignificant dose to healthy tissues.
肝脏恶性肿瘤是全球癌症相关死亡的最常见原因之一。动脉内注射标记有发射β射线放射性核素的微粒是治疗肝癌的一种有前景的非手术方法。
在这项工作中，基于正常Wistar大鼠的生物分布数据，估算了成年男性钬羟基磷灰石（Ho-HA）放射性药物的辐射吸收剂量。应用了MIRD剂量计算方法以及斯帕克斯和艾多安方法。
结果表明，超过84% 的吸收剂量集中在肝脏组织中（7.35 mGy/MBq）。此外，Ho-HA对红骨髓、成骨细胞和脾脏组织的辐射吸收剂量估计分别约为0.18、0.38和0.24 mGy/MBq。最大给药活度在87.5 MBq/kg体重时获得，有效剂量为0.39 mSv/MBq。肝脏组织的最大耐受剂量（MTD）为6.13 GBq（165.56 mCi）。
本研究表明，Ho-HA可为肝癌恶性肿瘤提供可观的剂量，而对健康组织的剂量微不足道。
Zotero 插件
